Hopes have risen for a new treatment option for a rare and severe form of childhood epilepsy, Dravet syndrome, after Biogen and Stoke Therapeutics reported new data for their recently partnered ...

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico and the US.

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, outside the U.S.

Meanwhile, Biogen will hold exclusive rights to commercialize the therapy in the rest of the world, expanding access to the treatment for Dravet syndrome patients globally.

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

The companies said Biogen will also chip in 30% of external clinical development costs for zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a genetic ...

Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.

About Dravet Syndrome Dravet syndrome is a severe developmental and epileptic encephalopathy characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS ...